Data Snapshots

Get It Delivered

Get research news and insights based on consensus data provided by Visible Alpha, delivered to your inbox.

May 15, 2025

Indian banks to face margin squeeze as monetary easing gains pace

Indian banks are likely to see further pressure on lending margins as the Reserve Bank of India (RBI) continues its monetary easing cycle. Net interest margins (NIMs) — a key gauge of bank profitability — are expected to continue…

May 13, 2025

Soleno’s rare disease drug off to brisk start following FDA nod

Soleno Therapeutics Inc. (NASDAQ: SLNO) marked a major breakthrough in the first quarter of 2025 with US regulatory approval for VYKAT XR, the first treatment available for hyperphagia—a chronic and life-threatening symptom—in…

May 13, 2025

Flywire beats Q1 estimates on Sertifi boost, reaffirms 2025 outlook

U.S. payments processor Flywire Corp. (NASDAQ: FLYW) recently reported its Q1 2025 earnings, revealing stronger-than-expected operating revenue of $128.7 million, outperforming Visible Alpha consensus expectations of $124 million,…

May 09, 2025

Pyxis Oncology pins hope on lead cancer drug following FDA fast track nod

Pyxis Oncology (NASDAQ: PYXS) has narrowed its pipeline to a single cancer drug, micvotabart pelidotin (PYX-201), as it races to capitalize on rising investor interest in antibody-drug conjugates (ADCs). The US biotech earlier…

May 07, 2025

Nintendo to face weak results, but analysts eye rebound with next-gen gaming console

Nintendo (TSE: 7974) is expected to report its full-year fiscal 2025 financial results on Thursday, May 8, with analysts projecting a steep year-on-year decline in sales as its flagship console nears the end of its lifecycle. Consensus…

May 05, 2025

Gold to continue its rally as geopolitical shifts, central banks, and Basel III drive demand

Gold prices surged to record highs in the first quarter of 2025, as macroeconomic and geopolitical forces reshaped investor sentiment. The metal’s traditional role as a safe haven has been reinforced amid growing unease over…

May 05, 2025

Sangamo’s hemophilia A gene therapy revenue forecasts cut after Pfizer exit

Sangamo Therapeutics Inc. (NASDAQ: SGMO) entered 2025 on a weak footing after Pfizer Inc. (NYSE: PFE) withdrew from their joint hemophilia A gene therapy programme, sending Sangamo’s shares sharply lower. The pharmaceutical…

May 04, 2025

Viper Energy set for turnaround in natural gas business

Viper Energy Inc. (NASDAQ: VNOM), a royalty-focused subsidiary of Diamondback Energy (NASDAQ: FANG), is due to report first-quarter earnings on Monday, May 5. Analysts expect the Texas-based group to post revenue of $247 million,…

Apr 28, 2025

Slowing momentum: Aixtron faces weak demand in core chip segments

Aixtron SE (ETR: AIXA), the German chip systems manufacturer, is set to report first-quarter results on Wednesday, April 30, amid growing investor unease following a revenue warning in February that triggered the stock’s steepest…

Apr 23, 2025

Ola Electric’s spark fades amid rising competition and mounting losses

Ola Electric Mobility (NSE: OLAELEC), India’s leading electric two-wheeler maker, is struggling to maintain its early lead in a fast-growing but increasingly competitive market. Shares have plunged more than 60% since their…

Apr 23, 2025

NXP Semiconductors’ Q1 revenue set to slide further

NXP Semiconductors NV (NASDAQ: NXPI) will report first-quarter earnings on Monday, April 28, as the Dutch chipmaker grapples with a deepening slowdown in demand from its core automotive customers. After a difficult 2024 marked…

Apr 23, 2025

Bayer to spotlight Nubeqa data at AUA amid push for expanded use

Bayer AG (FWB: BAYN) is set to present new data for Nubeqa (darolutamide) in prostate cancer at the upcoming American Urological Association (AUA) Annual Meeting taking place in Las Vegas from April 26-29, 2025. Originally…

Apr 22, 2025

Johnson & Johnson and Legend Biotech’s Carvykti to hit blockbuster status in 2025

Johnson & Johnson (NYSE: JNJ) and Legend Biotech (NASDAQ: LEGN) are making a $150 million bet on the future of cell therapy, with plans to build a new manufacturing facility in Belgium aimed at doubling output of their cancer…

Apr 17, 2025

LVMH under pressure as luxury slowdown deepens across key markets

Luxury goods group LVMH (EPA: MC), owner of brands such as Louis Vuitton, Moët & Chandon, and Hennessy, is the first major European player to report Q1 earnings since U.S. President Donald Trump’s announcement — and then…

Apr 16, 2025

Novartis strikes Huntington’s drug deal as U.S. expansion plans gather pace

Novartis (SWX: NOVN) has completed a global licensing and collaboration deal with U.S.-based PTC Therapeutics (NASDAQ: PTCT) for the development of PTC518, an experimental oral treatment for Huntington’s disease, as the Swiss…

Get it Delivered

Get articles like these including investment research news and insights uncovered using the Visible Alpha platform delivered to your inbox.

Subscribe Now

Data Snapshots

Get It Delivered

Indian banks to face margin squeeze as monetary easing gains pace

Soleno’s rare disease drug off to brisk start following FDA nod

Flywire beats Q1 estimates on Sertifi boost, reaffirms 2025 outlook

Pyxis Oncology pins hope on lead cancer drug following FDA fast track nod

Nintendo to face weak results, but analysts eye rebound with next-gen gaming console

Gold to continue its rally as geopolitical shifts, central banks, and Basel III drive demand

Sangamo’s hemophilia A gene therapy revenue forecasts cut after Pfizer exit

Viper Energy set for turnaround in natural gas business

Slowing momentum: Aixtron faces weak demand in core chip segments

Ola Electric’s spark fades amid rising competition and mounting losses

NXP Semiconductors’ Q1 revenue set to slide further

Bayer to spotlight Nubeqa data at AUA amid push for expanded use

Johnson & Johnson and Legend Biotech’s Carvykti to hit blockbuster status in 2025

LVMH under pressure as luxury slowdown deepens across key markets

Novartis strikes Huntington’s drug deal as U.S. expansion plans gather pace

Get it Delivered

Call Us

Company

Products

Client Access